An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.

2024-510995-18-00 Protocol IDE397-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 1 Mar 2023 · Status Ongoing, recruitment ended · 3 EU/EEA countries · 14 sites · Protocol IDE397-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 130
Countries 3
Sites 14

Advanced Solid Tumors

Key facts

Sponsor
Ideaya Biosciences Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
1 Mar 2023 → ongoing
Decision date (initial)
2024-03-25
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-510995-18-00
EudraCT number
2022-002607-37
ClinicalTrials.gov
NCT04794699

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Ideaya Biosciences Inc.

Sponsor organisation
Ideaya Biosciences Inc.
Address
7000 Shoreline Court Suite 350
City
South San Francisco
Postcode
94080-7604
Country
United States

Scientific contact point

Organisation
Ideaya Biosciences Inc.
Contact name
Ideaya Scientific contact point

Public contact point

Organisation
Ideaya Biosciences Inc.
Contact name
Ideaya Public contact point

Locations

3 EU/EEA countries · 14 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 15 6
Germany Ended 15 1
Spain Ongoing, recruitment ended 15 7
Rest of world
United States, Taiwan, Australia, Korea, Republic of
85

Investigational sites

France

6 sites · Ongoing, recruitment ended
Centre Hospitalier Universitaire De Toulouse
Oncologie Médicale, 1 Avenue Irene Joliot Curie, 31059, Toulouse Cedex 9
Institut Gustave Roussy
Medical Oncology, 114 Rue Edouard Vaillant, 94800, Villejuif
Centre Hospitalier Regional De Marseille
CEPCM, 264 Rue Saint Pierre, 13005, Marseille
Institut Bergonié
Oncologie Médicale, 229 cours de l'Argonne, 33076, Bordeaux
Centre Eugène Marquis
Oncologie médicale, Avenue de la Bataille de Flandres Dunkerque, 35000, Rennes
Centr Georges Francois Leclerc
Medical Oncology, 1 Rue Professeur Marion, 21000, Dijon

Germany

1 site · Ended
University Medical Center Hamburg-Eppendorf
Dept. Medicine II, Martinistrasse 52, Eppendorf, Hamburg

Spain

7 sites · Ongoing, recruitment ended
Hospital Universitario 12 De Octubre
Medical Oncology, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitario Quironsalud Madrid
Medical Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario Hm Sanchinarro
Medical Oncology, Calle Ona 10, 28050, Madrid
Hospital Universitari Vall D Hebron
Medical Oncology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital Quironsalud Barcelona
Medical Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Medical Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Fundacion Instituto Valenciano De Oncologia
Medical Oncology, Calle Professor Beltran Baguena 8, 46009, Valencia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2023-03-01 2023-03-21 2026-03-10
Germany 2024-01-22
Spain 2023-07-04 2023-07-24 2026-03-10

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Corrective measures 1 · Art. 77 CTR

Corrective measure CM-DE-0001

Member state
Germany
Publication date
2024-07-16
Type
4
Reason
7
Immediate action required
No
Justification
ASR-2024-00315, DE-0000000054. See proposed CM.

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-15 Germany Acceptable
2024-03-20
2024-03-21
2 SUBSTANTIAL MODIFICATION SM-1 2024-05-17 Germany Acceptable
2024-07-29
2024-07-30
3 SUBSTANTIAL MODIFICATION SM-2 2024-08-23 Germany Acceptable
2024-11-08
2024-11-08
4 SUBSTANTIAL MODIFICATION SM-3 2024-12-18 Germany Acceptable
2025-03-25
2025-03-26
5 SUBSTANTIAL MODIFICATION SM-4 2025-06-30 Germany Acceptable
2025-09-22
2025-09-23
6 SUBSTANTIAL MODIFICATION SM-5 2025-11-27 Germany Acceptable
2026-02-02
2026-02-02